Full Press Release Details
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
May 31, 2026, VSee Health, Inc., a Delaware corporation (the "Company") entered into a Stock Purchase Agreement (the "Purchase
Agreement") with Milton Chen, the Company's co-Chief Executive Officer and Chairman of the Board and the Chief Executive
Officer of VSee Lab, Inc., a Delaware Corporation and wholly-owned subsidiary of the Company ("VSee Lab"). Pursuant to the
Purchase Agreement, Mr. Chen agreed to purchase, and the Company agreed to sell to Mr. Chen, on the May 31, 2026 (the "Closing
Date"), all of the equity securities of VSee Lab (the "VSee Lab Stock"), free and clear of all liens and encumbrances.
Under the Purchase Agreement, Mr. Chen is solely responsible for causing the Company to satisfy any and all indebtedness and other liabilities
of VSee Lab that are not paid as of the closing contemplated by the Purchase Agreement (the "Closing") and the Company will
have no obligation with respect thereto. Notwithstanding, the Company will retain, pay, perform and discharge and remain solely responsible
for, any and all liabilities, obligations or commitments of VSee Lab or relating to the ownership or operation of VSee Lab related to
any period, event, circumstance or condition occurring prior to the Closing Date, including any liabilities relating to taxes for any
and all taxes attributable to any taxable period ending on or before the Closing Date and the portion through the Closing Date for any
taxable period that includes, but does not end, on the Closing Date, other than sales and use taxes accrued at the company level, which
will remain an obligation of VSee Lab, regardless of the time period of when such obligation were incurred and except to the extent expressly
assumed by Mr. Chen pursuant to the Purchase Agreement.
consideration for the VSee Lab Stock and the mutual release of liability set forth in the Purchase Agreement, Mr. Chen has agreed to
transfer to the Company all of the common stock, par value $0.0001 per share (the "Common Stock"), of the Company that he
currently owns, or 2,870,069 shares of Common Stock. In connection with the execution of the Purchase Agreement, Mr. Chen resigned as
co-Chief Executive Officer and chairman of the board of directors of the Company, effective as of the Closing Date.
following unaudited pro forma condensed consolidated balance sheet as of March 31, 2026, is presented as if the Transaction, as described
in the notes to these unaudited pro forma condensed consolidated financial statements, had occurred on March 31, 2026.
unaudited pro forma condensed consolidated statements of operations for the three months ended March 31, 2026, and the year ended December
31, 2025, are presented as if the Transaction had occurred on January 1, 2025. All adjustments shown in the unaudited
forma condensed consolidated financial statements are transaction accounting adjustments.
unaudited pro forma condensed consolidated financial statements were prepared in accordance with Article 11 of Regulation S-X. Such unaudited
pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative
of the results of operations that would have been achieved had the events reflected been completed as of the dates indicated or of the
results that may be obtained in the future. The unaudited pro forma condensed consolidated statement of operations is based on management's
estimate of the effects on the financial statements of the Transaction. Pro forma adjustments are based on currently available information,
historical results and certain assumptions that management believes are reasonable and are described in the accompanying notes.
PROFORMA CONDENSED CONSOLIDATED BALANCE SHEET
| Historical (Unaudited) | Pro forma adjustment | Pro forma | |||||||||||||
| ASSETS | |||||||||||||||
| Current assets | |||||||||||||||
| Cash | $ | 1,346,132 | $ | (101,616 | ) | (f) | $ | 1,244,516 | |||||||
| Accounts receivable, net of allowance for credit losses of $1,190,801 as of March 31, 2026 | 2,671,169 | (298,705 | ) | (f) | 2,372,464 | ||||||||||
| Due from related party | 312,947 | - | 312,947 | ||||||||||||
| Prepaids and other current assets | 511,051 | (145,042 | ) | 366,009 | |||||||||||
| Total current assets | 4,841,299 | (545,363 | ) | 4,295,936 | |||||||||||
| Non-current assets | |||||||||||||||
| Long-term investments | 749,800 | - | 749,800 | ||||||||||||
| Right-of-use assets, net | 10,881 | - | 10,881 | ||||||||||||
| Intangible assets, net | 8,232,500 | - | 8,232,500 | ||||||||||||
| Goodwill | 4,916,694 | - | 4,916,694 | ||||||||||||
| Fixed assets, net | 265,245 | (60,151 | ) | (f) | 205,094 | ||||||||||
| Total assets | $ | 19,016,419 | $ | (605,514 | ) | $ | 18,410,905 | ||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||||
| Current liabilities | |||||||||||||||
| Accounts payable and accrued liabilities | $ | 8,529,725 | $ | (2,216,512 | ) | (f) | $ | 6,313,213 | |||||||
| Deferred revenue | 1,446,585 | (1,446,585 | ) | (f) | - | ||||||||||
| Due to related party | 51,900 | - | 51,900 | ||||||||||||
| Operating lease liabilities | 10,881 | - | 10,881 | ||||||||||||
| Encompass Purchase Liability | 400,000 | - | 400,000 | ||||||||||||
| Convertible Note, at fair value | 346,943 | - | 346,943 | ||||||||||||
| Loan payable, related party | 471,651 | (330,000 | ) | (f) | 141,651 | ||||||||||
| Notes payable, net of discount | 524,093 | - | 524,093 | ||||||||||||
| Common stock issuance obligation | 12,798 | - | 12,798 | ||||||||||||
| Total current liabilities | $ | 11,794,576 | $ | (3,993,097 | ) | $ | 7,801,479 | ||||||||
| Non-current liabilities | |||||||||||||||
| Notes payable, less current portion, net of discount | 781,581 | - | 781,581 | ||||||||||||
| Deferred tax liability | 119,192 | - | 119,192 | ||||||||||||
| Total liabilities | $ | 12,695,349 | $ | (3,993,097 | ) | $ | 8,702,252 | ||||||||
| STOCKHOLDERS' EQUITY | |||||||||||||||
| Series A Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 422 shares issued and outstanding as of March 31, 2026 | 1 | - | 1 | ||||||||||||
| Series B Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 2,000 shares issued and outstanding as of March 31, 2026 | 1 | - | 1 | ||||||||||||
| Common stock, $0.0001 par value; 100,000,000 shares authorized 44,429,352 shares issued and outstanding as of March 31, 2026 | 4,730 | - | 4,730 | ||||||||||||
| Treasury stock, at cost; 2,870,069 shares held as of March 31, 2026 | - | (545,313 | ) | (e) | (545,313 | ) | |||||||||
| Additional paid-in capital | 91,333,323 | - | 91,333,323 | ||||||||||||
| Accumulated deficit | (85,016,985 | ) | 3,932,896 | (f) | (81,084,089 | ) | |||||||||
| Total stockholders' equity | 6,321,070 | 3,387,583 | 9,708,653 | ||||||||||||
| Total liabilities and stockholders' equity | $ | 19,016,419 | $ | (605,514 | ) | $ | 18,410,905 |
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THE THREE MONTHS ENDED MARCH 31, 2026
| Historical | Pro forma adjustment | Pro Forma | |||||||||||||
| Revenues | |||||||||||||||
| Subscription fees | $ | 605,470 | $ | (605,470 | ) | (a) | $ | - | |||||||
| Professional services and other fees | 606,745 | (606,745 | ) | (a) | - | ||||||||||
| Technical engineering fees | 68,677 | (68,677 | ) | (a) | - | ||||||||||
| Patient fees | 881,340 | - | 881,340 | ||||||||||||
| Telehealth fees | 997,953 | - | 997,953 | ||||||||||||
| Total revenues | 3,160,185 | (1,280,892 | ) | 1,879,293 | |||||||||||
| Cost of revenues | 1,962,074 | (810,194 | ) | (a) | 1,151,880 | ||||||||||
| Gross margin | 1,198,111 | (470,698 | ) | 727,413 | |||||||||||
| - | |||||||||||||||
| Operating expenses | - | ||||||||||||||
| Compensation and related benefits | 1,732,003 | (1,482,984 | ) | (b) | 249,019 | ||||||||||
| General and administrative | 2,440,383 | (302,452 | ) | (b) | 2,137,931 | ||||||||||
| Total operating expenses | 4,172,386 | (1,785,436 | ) | 2,386,950 | |||||||||||
| Net operating loss | (2,974,275 | ) | 1,314,738 | (1,659,537 | ) | ||||||||||
| - | |||||||||||||||
| Other income (expense) | - | ||||||||||||||
| Interest expense | (113,098 | ) | 21,155 | (b) | (91,943 | ) | |||||||||
| Change in fair value of financial instruments | 143,040 | - | 143,040 | ||||||||||||
| Gain on extinguishment of financial liabilities | 367,809 | - | 367,809 | ||||||||||||
| Total other income (expense), net | 397,751 | 21,155 | 418,906 | ||||||||||||
| Loss before provision for income taxes | (2,576,524 | ) | (1,335,893 | ) | (1,240,631 | ) | |||||||||
| Provision for income taxes | (23,738 | ) | (513 | ) | (d) | (24,251 | ) | ||||||||
| Net loss | $ | (2,600,262 | ) | $ | (1,355,380 | ) | $ | (1,264,882 | ) | ||||||
| Basic and diluted loss per common share | $ | (0.05 | ) | $ | - | $ | (0.03 | ) | |||||||
| Weighted average number of common shares outstanding, basic and diluted | 47,902,512 | - | 45,032,443 |
PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THE YEAR ENDED DECEMBER 31, 2025
| Historical (Audited) | Pro forma adjustment | Pro Forma | |||||||||||||
| Revenues | |||||||||||||||
| Subscription fees | $ | 3,230,239 | $ | (3,230,239 | ) | (a) | $ | - | |||||||
| Professional services and other fees | 3,042,688 | (3,042,398 | ) | (a) | 290 | ||||||||||
| Technical engineering fees | 1,042,593 | (1,042,593 | ) | (a) | - | ||||||||||
| Patient fees | 3,377,536 | - | 3,377,536 | ||||||||||||
| Telehealth fees | 3,922,628 | - | 3,922,628 | ||||||||||||
| Institutional fees | 2,500 | - | 2,500 | ||||||||||||
| Total revenues | 14,618,184 | (7,315,230 | ) | 7,302,954 | |||||||||||
| Cost of revenues | 7,262,219 | (3,901,878 | ) | (a) | 3,360,341 | ||||||||||
| Gross margin | 7,355,965 | (3,413,352 | ) | 3,942,613 | |||||||||||
| Operating expenses | |||||||||||||||
| Compensation and related benefits | 6,901,583 | (4,220,844 | ) | (b) | 2,680,739 | ||||||||||
| General and administrative | 10,037,275 | (1,272,967 | ) | (b) | 8,764,308 | ||||||||||
| Total operating expenses | 16,938,858 | (5,493,811 | ) | 11,445,047 | |||||||||||
| Net operating loss | (9,582,893 | ) | 2,080,459 | (7,502,434 | ) | ||||||||||
| Other income (expense) | |||||||||||||||
| Interest expense | (2,811,861 | ) | 85,796 | (b) | (2,897,665 | ) | |||||||||
| Other income (expense), net | 47,429 | (15,429 | ) | (b) | 62,858 | ||||||||||
| Change in fair value of financial instruments | (1,450,271 | ) | - | (1,450,271 | ) | ||||||||||
| Loss on extinguishment of loan | (221,202 | ) | - | (221,202 | ) | ||||||||||
| Loss on issuance of financial instrument | (668,020 | ) | - | (668,020 | ) | ||||||||||
| Gain on disposal of subsidiaries | - | 2,599,736 | (c) | 2,599,736 | |||||||||||
| Total other income (expense), net | (5,061,531 | ) | 2,670,103 | (2,574,564 | ) | ||||||||||
| Loss before benefit from (provision for) income taxes | (14,644,424 | ) | 4,750,562 | (10,076,998 | ) | ||||||||||
| Provision for income taxes | (68,426 | ) | (35,823 | ) | (d) | (104,249 | ) | ||||||||
| Net loss | $ | (14,712,850 | ) | $ | 4,786,385 | $ | (9,972,749 | ) | |||||||
| Basic and diluted loss per common share | $ | (0.73 | ) | $ | - | $ | (0.58 | ) | |||||||
| Weighted average number of common shares outstanding, basic and diluted | 20,143,393 | - | 17,273,324 |
TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
1 - Basis of Presentation
unaudited pro forma consolidated balance sheet and statements of operations are based upon the historical consolidated financial statements
of VSee Health, Inc. (the "Company"), which were included in its Quarterly Report on Form 10-Q for the three months ended
March 31, 2026, and its Annual Report on Form 10-K for the year ended December 31, 2025. Unless the context indicates otherwise, any
reference in this report to the "Company," "we," "us," and "our" refers to VSee Health,
unaudited pro forma condensed consolidated statements of operations reflect the disposal of the Company's wholly owned subsidiary,
VSee Lab, Inc, as if the disposal had been consummated on January 1, 2025. The unaudited pro forma condensed consolidated balance sheet
as of March 31, 2026, reflect such sale as if it had been consummated on that date.
2 - Pro Forma Adjustments
This adjustment reflects the elimination of revenues and cost of revenues of VSee Labs and it's 100% subsidiary i.e. This American
This adjustment reflects the elimination of operating expenses and other income (expense), net of the VSee Labs and TAD business.
This adjustment reflects the gain arising from the transaction as of May 31, 2026.
This adjustment represents the estimated income tax effect of the pro-forma adjustments. The tax effect of the pro-forma adjustments
was calculated using the historical statutory rates in effect for the periods presented.
This adjustment represents the consideration in the form of stock repurchase at the closing of the transaction.
These adjustments reflect the elimination of assets and liabilities attributable to VSee Lab, Inc.